Dr. Salkeni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8613 Route 29
Ste 200N
Fairfax, VA 22031Phone+1 571-350-8400Fax+1 703-280-9596
Summary
- Dr. Mohamad Adham Salkeni is an oncologist in Morgantown, WV and is an Associate Professor at West Virginia University. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 12 years. He specializes in hematology and oncology.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 2006 - 2010
Damascus University Faculty of MedicineClass of 2004
Certifications & Licensure
VA State Medical License 2022 - 2026
WV State Medical License 2012 - 2025
PA State Medical License 2020 - 2022
OH State Medical License 2010 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Publications & Presentations
PubMed
- 8 citationsSapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.Bora Lim, David Potter, Mohamad Adham Salkeni, Paula Silverman, Tufia C. Haddad
Clinical Cancer Research. 2021-04-05 - 85 citationsA Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid MalignanciesTrisha Wise-Draper, Ganesh Moorthy, Mohamad Adham Salkeni, Nagla Abdel Karim, Hala Elnakat Thomas
Targeted Oncology. 2017-06-01 - 52 citationsSafety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10Jame Abraham, A Montero, Rachel C. Jankowitz, Mohamad Adham Salkeni, Jan H. Beumer
Journal of Clinical Oncology. 2019-08-23
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
